Robert Brenner

Dr. Robert Brenner is Co-Founder and CEO of Cru Bio. He is a respected nephrologist with over two decades as a successful biotechnology executive.

Robert started his career at Amgen, where he led kidney related global development programs and supported two product approvals. Thereafter, he was a member of the executive team at Amag Pharmaceuticals, contributing to their first therapeutic approval and launch.

Robert then served as CEO at AlloCure, a privately held, clinical stage regenerative medicine company in the kidney space. He also served as CMO at Orionis Biosciences and EVP of Research and Development at Codiak.

In recent years, Dr. Brenner has worked in healthcare venture capital and participated in the incubation and launch of new kidney companies in both the US and China.

Robert received his B.A. from Johns Hopkins University and his M.D. from Albert Einstein College of Medicine. He completed his medical residency at Brigham and Women’s Hospital and his nephrology fellowship at Stanford University Medical Center.